Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You've described yourself quite well!
Well, believe what you want to believe, deny what you wish to deny. In the end, feeling what will matter most won't be number counts one way or the other, but who actually was afforded the opportunity to survive the pandemic (the lucky ones), and who didn't (the unlucky ones). Elevated happiness in many homes verses deep sadness of loss in many others.
I feel the use of your cold-cut reference as a portrayal to the later above is a bit over the top and callous to the circumstances at hand. JMO
Every minute, 114 Americans are testing positive for COVID-19, according to Johns Hopkins University data. Every hour, 65 Americans are dying.
Let us not forget the words spoken in early November of this year from Ohio Gov. Mike DeWine saying that "COVID is coming after All of Us"!!!
It's a holiday week and the M/M's who run the game here always take advantage of the IPIX stock price on holiday weeks, when folk's thoughts are elsewhere and busyness abounds. They'll use it to their advantage to squeeze out the last drop of strength to hold, by driving down the share price on low volume, while trying to make it appear as if extreme weakness and fear was hovering over the stock. Check the past holiday history, it's the same game over and over again. Damn them to Hell I say!
FDA Authorizes Regeneron's Covid-19 Antibody Cocktail Drug
https://www.msn.com/en-us/health/health-news/fda-authorizes-regenerons-covid-19-antibody-cocktail-drug/ar-BB1bf56s?li=BBnb7Kz
Immunity to the Coronavirus May Last Years, New Data Hint - NY Times
https://www.msn.com/en-us/health/medical/immunity-to-the-coronavirus-may-last-years-new-data-hint/ar-BB1b6dwt?li=BBnb7Kz
This OTC, mkt/maker, manipulated, criminal-minded, masked-bandit of an exchange is a total train-wreck and whack-job at each and every turn!!!
Not just any cigar! I would assume they'd be Cubans!
And you want me to take your counter remark as factual?
Forget About It!
I've noticed that since PFE's 90% announcement the other week, the mention of Therapeutics seems to of vanished across the airwaves. It has now become all about Vaccine!, Vaccine!, Vaccine!
Paraphrasing our skewed and out-going POTUS's use of style in communicating (Covid!, Covid!, Covid!). :)
...and what's up with this continuing oppression placed upon IPIX's share price movement? Something really stinks ferociously in the China Sea!
Perhaps the CTA application is not limited to just one individual country, but involves the entire European Union's health agency as a whole!
My birthday has the same pattern! ;)
The Next Big Challenge After a Covid Vaccine Is Giving It to Enough People
The Wall Street Journal
Max Colchester, Drew Hinshaw
https://www.msn.com/en-us/health/medical/the-next-big-challenge-after-a-covid-vaccine-is-giving-it-to-enough-people/ar-BB1aQymP?li=BBnb7Kz
Looks like that trailing gap has finally filled!
Does this person have Leo's consent to discuss any and all particulars pertaining to Brilacidin?
If not, perhaps he or she should obtain it first, at least out of courtesy to Leo!
Investigational drug Brilacidin shows efficacy against Covid in lab testing, finds study. The study says the drug has demonstrated synergistic antiviral activity when combined with remdesivir.
HIMANI CHANDNA 1 November, 2020 5:29 pm IST
https://theprint.in/health/investigational-drug-brilacidin-shows-efficacy-against-covid-in-lab-testing-finds-study/535032/
New Delhi: A new investigational drug, Brilacidin, has shown efficacy against Covid-19 and is likely to work better when given with remdesivir, said a study published by MedRxiv, a portal for preprints or preliminary reports that have not been peer-reviewed. MedRxiv, read as med-archive, was founded by Cold Spring Harbor Laboratory (CSHL), a not-for-profit research institution, along with Yale University, and the peer-reviewed British Medical Journal (BMJ). Brilacidin, manufactured by US-based Innovation Pharmaceuticals, is modeled after Host Defense Proteins (HDPs), which are the “front-line” of defense in the body’s innate immune system. The study, uploaded on 30 October, titled Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2 demonstrates that the investigational drug “is capable of exerting potent in-vitro (in test-tubes) antiviral activity against SARS-CoV-2, both as a standalone treatment and in combination with remdesivir, which is currently the only FDA-approved drug for the treatment of covid-19.” The drug is a synthetic, non-peptide small molecule which, according to its manufacturer, kills pathogens swiftly, significantly reducing the likelihood of drug resistance among patients. “Just as importantly, Brilacidin functions in a robust immunomodulatory capacity, lessening inflammation and promoting healing,” the company website said.
Explaining the mechanism of its working, the paper, authored by eight US-based researchers, concludes that the drug appears to act by disrupting viral integrity and blocking the viral entry into human cells. It further added that “combining the drug with antiviral treatments that have a different mechanism of action” may produce better and enhanced results. “The potential for brilacidin to exert a synergistic inhibition of SARS-CoV-2 when combined with current frontline Covid-19 antiviral treatments, namely, remdesivir and favipiravir, was assessed,” the researchers found. The drug was tested for potential toxicity when taken in combination of remdesivir or favipiravir. However, “no apparent toxicity could be detected…,” the paper said. The combination of brilacidin with remdesivir was noticed to reduce the viral load by more than 99 per cent, “thus providing a highly effective inhibition profile and achieving greater inhibition than with either compound alone…”The data may also support the drug’s ability to interfere with the interaction between the spike proteins of the coronavirus and Angiotensin-converting enzyme 2 (ACE2) Receptor —which is more likely to be the cell receptor through which the virus invades the host cell.
Brilacidin belongs to the latest class of antibiotics the manufacturer has dubbed “defensin-mimetic” which have anti-inflammatory, antibiotic and antiviral properties. According to the drug maker, the new class antibiotics are considered attractive candidates given favorable characteristics, including being highly selective (potent against target while leaving host cells unaffected), not prone to resistance mechanisms, relatively easy to produce at low costs and stable during storage or upon administration.
I like to go places on two wheels as much as possible these days, while wearing my modular full-face motorcycle helmet. When I get to where I'm going I just make sure the face shield is in the fully closed lock-down position, and away I go. I don't fiddle around with a mask unless it's an absolute necessary must. Kids like it too, they think I'm a monster or an alien buying groceries! :)
You can't be satisfied, not even for one day. Why is that?
U.S. to Secure Up to 1 Million Doses of Experimental COVID-19 Antibody Drug
https://www.newsweek.com/us-secure-1-million-doses-experimental-covid-19-antibody-drug-similar-one-trump-took-1542943
Actually I had contemplated on the same thought.
Yes it's true he tested positive and if he isn't the toughest in the world he sure thinks he is!
If he won't take it willingly shove it down his throat!
President Trump and 1st Lady both test positive for Covid-19 10:00pm PT twitter tweet!
Probably not going to happen anytime soon... Brilacidin is just showing to good of results thus far and becomes an obstacle to the flow of all that high-priced revenue starting to saturate Gilead's pocketbook!
MSN Article: Remdesivir may not cure coronavirus, but it’s on track to make billions for Gilead.
https://www.msn.com/en-us/news/us/remdesivir-may-not-cure-coronavirus-but-its-on-track-to-make-billions-for-gilead/ar-BB19z4E5?li=BBnb7Kz
Excerpts only, not the full article are listed below.
M/M's selling the news/share price hike with naked shares then retracing the price back down to cover those sales along with some froth for themselves. It's the game they play!
Yet another in a long line of positive check marks from the RBL that Brilacidin is in fact the best treatment tested thus far against the COVID line of virus!
10K out!
Stay strong and positive! Best to you Alan, we’ll see you soon!
Thanks for posting... very persuading and seems to be a high percentage of sound probability.
What the hey? You just had a thought and then wished it up?
August 26, 2020
Dr. William F. DeGrado, a Discoverer of Brilacidin, Joins Innovation Pharmaceuticals as Scientific Advisor
This isn't a Market... this is a Manipulators paradise! :>)
Charles Schwab has had it showing since the release early this morning
ARCA has an ask offer for 1,000 shares @ $12.00 bucks a piece... Taker's?